Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-SMC condensin I complex subunit H (NCAPH)
- Target
- NCAPH
- Molecular classification
- Chromosome structural protein, Kleisin family protein, Condensin I complex subunit, Other
01
Overview
Non-SMC condensin I complex subunit H (NCAPH) is a regulatory kleisin subunit of the condensin I complex, essential for the conversion of interphase chromatin into condensed mitotic chromosomes[1][2][4]. NCAPH ensures proper chromosome condensation, chromatid cohesion, and segregation, playing a key role in maintaining genomic stability and the integrity of cell division[1][2][5]. It also participates in DNA damage responses by recruiting and stabilizing specific DNA repair factors (such as GEN1), especially during DNA inter-strand crosslink repair[3][5]. NCAPH is overexpressed in a variety of cancers, promoting tumor cell proliferation, migration, and invasion, and is regarded as both a prognostic biomarker and a potential therapeutic target[2][5][6]. Loss or dysregulation of NCAPH leads to chromosome mis-segregation, cell cycle arrest, increased DNA damage, and apoptosis[3][5]. No currently approved drugs are known to target NCAPH directly as of the latest available data.
- Other names
- Condensin complex subunit 2CAP-HChromosome-associated protein HBarren homolog protein 1BRRN1KIAA0074hCAP-HCAPHMCPH23NCAPH1XCAP-H homologbarren homolog 1
02
Biological functions
Chromosome condensationRegulation of mitosis/cell cycleChromatid segregationDNA damage response and repairMaintenance of genomic stabilityCell proliferation
03
Disease associations
Cancer (including colon, pancreatic, hepatocellular, lung, cervical, gastric, bladder, endometrial, renal, prostate, and breast cancer)Microcephaly (Microcephaly 23, primary, autosomal recessive; Microcephaly 19, primary, autosomal recessive)Other
04
Safety considerations
Disruption causes chromosomal instability, errors in chromosome segregation, cell death, and possibly developmental defects[3][5]
05
Biomarkers
Prognostic biomarker in multiple cancers (elevated NCAPH indicates aggressive tumor behavior)Potential sensitivity marker for certain chemotherapies/radiotherapies[2]
Beyond the preview
Go deeper on Non-SMC condensin I complex subunit H (NCAPH).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Non-SMC condensin I complex subunit H (NCAPH).